

# **Section and Analys Sonference**

Zurich, 11 March 2025

Postbox



# Further pursuit of integrated healthcare



### Increased market share

# E Improved profitability



### «Consultation plus» established



# Clarity in the home care business



# Progress in digitalisation



# 43.5%

### **Pharmaceutical Market Growth**

© IQVIA - Swiss pharmaceutical market December 2024



# 

Galenica Net Sales Growth



### Net new locations (+2.7%)

SANITA

0

*∰* Galenica




### Omni-Channel to further gain importance





### **E-prescriptions redeemable in all Galenica pharmacies**





VERFORA

ERFORA Triofan

VERACTIV

MAGNESIUN


Triofan

### Verfora continued grow and expand its market position





### Home Care continues to be an area for growth



=Gale

## Wholesale

### Net sales growthe at



# Go-live of new ERP system in Lausanne-Ecublens

(010

0

*G*alenica

A

### Higher efficiency in transport services thanks to Health Supply

*(*Galenica



# 27.5% Gross Margin



# La Constant de la Con



# 4%

### Profit from cont. operations adjusted<sup>1</sup>


1 Excluding the effects of IFRS 16 and IAS 19



# CHF 61 million

### Free Cash Flow<sup>1</sup>

1 Excluding the effects of IFRS 16 and IAS 19



### Slight increase in market growth expected for 2025







### **Sales Guidance**

### **EBIT Guidance<sup>1</sup>**

1 Excluding the effects of IFRS 16 and IAS 19



Added value in the network We generate value for customers and partners

> Omni-Channel Health Services & Products

> > Strategy

Sustainably successful We work efficiently and effectively

> Efficiency Sustainability (ESG)



00

**Shaping the future** We are shaping the healthcare of tomorrow

Digital Health Connecting Healthcare

Strategy

### Pioneers in transition

We rethink and move forward together

Transformation Employer of choice

There for you every day. #StrongTogether

Activation

G









### **Galenica Investor Day 2025**

Save the date: 28 October 2025





### Disclaimer

### **Disclaimer Galenica**

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated develop-ment. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements, which speak only as of the date of this presentation.

### Disclaimer IQVIA © 2025, IQVIA AG

All rights reserved. The information may not be duplicated, stored, processed further, nor be made accessible in whole or in part to any third party without prior express and valid written permission of IQVIA AG. Terms used in connection with data/figures such as "patient", "doctor", "medical practice", "prescriber", or "phar-macy" do not designate any personal data but exclusively anonymous information (according to applicable, valid data protection laws).

IQVIA utilizes highly sophisticated technologies and methods in order to ensure that all its Information Services meet the applicable data protection requirements, regardless of the way data are combined.